Get the Stockscreener App
1.16
0.87%
0.01
Zyversa Therapeutics Inc stock is traded at $1.16, with a volume of 64,519.
It is up +0.87% in the last 24 hours and down -49.57% over the past month.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
See More
Previous Close:
$1.15
Open:
$1.14
24h Volume:
64,519
Relative Volume:
0.05
Market Cap:
$1.18M
Revenue:
-
Net Income/Loss:
$-98.30M
P/E Ratio:
-0.1609
EPS:
-7.2097
Net Cash Flow:
$-8.72M
1W Performance:
+2.65%
1M Performance:
-49.57%
6M Performance:
-73.64%
1Y Performance:
+51.83%
1-Day Range:
$1.11
$1.168
1-Week Range:
$1.0401
$1.2899
52-Week Range:
$0.541
$30.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Name
Zyversa Therapeutics Inc
Sector
Industry
Phone
908-370-5102
Address
217 W. MAIN STREET, SOMERVILLE
Compare ZVSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ZVSA | 1.16 | 1.18M | 0 | -98.30M | -8.72M | -7.2097 |
| VRTX | 446.08 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.77 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.86 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Zyversa Therapeutics Inc Stock (ZVSA) Latest News
ZyVersa reports progress on stroke-related heart injury treatment - Investing.com
ZyVersa Therapeutics Announces Peer-Reviewed Publication - GlobeNewswire
ZyVersa's IC 100 Shows Promise in Stroke Prevention, Phase 1 Trials Set for 2025 | ZVSA Stock News - StockTitan
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeu - GuruFocus.com
ZyVersa Therapeutics Reports Q3 Progress and Outlook - TipRanks
ZyVersa Therapeutics Inc (ZVSA) Quarterly 10-Q Report - Quartzy
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Plans Key Clinical Trials as Q3 Losses Narrow, Faces Cash Needs | ZVSA Stock News - StockTitan
ZVSA stock plunges to 52-week low, hitting $1.34 amid market challenges - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 3.56% - Investing.com India
ZyVersa Therapeutics, Inc. (ZVSA): A 38.8% Stock Surge Highlights Innovative Approach to Inflammatory Disease with IC 100 - BP Journal
Agrify Corporation (AGFY): Strategic Restructuring and New Leadership Boosts Stock by 33% as Green Thumb Invests $20 Million - BP Journal
Curis Inc. (CRIS) Stock Surges 5.08% Amid Strong Biotech Sector Performance - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge" - openPR
Wall Street-Heavily Traded - WDRB
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings - Benzinga
S&P 500 Gains 1%; Vimeo Shares Spike Higher - Benzinga
Bionomics Limited (BNOX): Stock Soars Over 162% Following Milestone Payment from Carina Biotech - BP Journal
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
ZyVersa (ZVSA) Stock Gains Momentum With Latest Research - Stocks Telegraph
U.S. Stock market: Zoomcar Holdings up 87.10%, Avalon GloboCare jumps 57.14%, Vimeo rises 44.07% among top gainers - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
ZyVersa reports progress on obesity inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa reports progress on obesity inflammation treatment - Investing.com India
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - The Manila Times
ZyVersa Therapeutics Highlights Published Data - GlobeNewswire
ZyVersa's Breakthrough: New Data Shows Promise for Type 2 Diabetes Prevention | ZVSA Stock | ZVSA Stock News - StockTitan
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - The Manila Times
ZyVersa Therapeutics Highlights Review Article Supporting - GlobeNewswire
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
ZyVersa reports obesity-linked brain inflammation study By Investing.com - Investing.com Canada
ZyVersa reports obesity-linked brain inflammation study - Investing.com
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewswire
ZVSA stock touches 52-week low at $2.07 amid sharp annual decline - Investing.com Canada
ZVSAZyVersa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
ZyVersa advances obesity drug with key milestones ahead - Investing.com India
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - The Manila Times
ZyVersa advances obesity drug with key milestones ahead By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to - The Bakersfield Californian
ZyVersa forms new SAB for obesity treatment advancement By Investing.com - Investing.com South Africa
ZyVersa forms new SAB for obesity treatment advancement - Investing.com India
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - The Manila Times
ZyVersa Therapeutics Forms New Scientific Advisory Board to - GlobeNewswire
Proteinuria Therapeutics Strategic Business Report 2024: Innovations in Biomarker-Based Diagnosis Sustain Growth in Proteinuria Therapeutics MarketForecasts to 2030 - 24matins.uk
Seelos Therapeutics, Inc. (SEEL): A Strategic Move with SLS-002 in the Fight Against PTSD - BP Journal
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Zyversa Therapeutics Inc Stock (ZVSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):